MSLN and ovarian carcinoma: In 2016, Tanyi and colleagues reported the results of a Phase I clinical investigation (NCT02159716) assessing the tumoricidal efficacy of 2nd-generation mesothelin-redirected CAR-Ts intravenously administered to six individuals with ovarian cancer (137).